[
    [
        {
            "time": "",
            "original_text": "华东医药:独家DPP-4抑制剂成药潜力明显,公司正从仿制向创新转型升级",
            "features": {
                "keywords": [
                    "华东医药",
                    "DPP-4抑制剂",
                    "成药潜力",
                    "仿制",
                    "创新",
                    "转型"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药:独家DPP-4抑制剂成药潜力明显,公司正从仿制向创新转型升级",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]